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Abstract
Data on the impact of the recently recommended maternal pertussis vaccination are promis-
ing, but still insufficient to universalise this approach. We thus compared the epidemiological
data prior to the implementation of this vaccination strategy in Argentina (2012) with the fig-
ures reported after 2012. During that 2010–2016 period, two outbreaks occurred, one in 2011
and another in 2016. In the former, the incidence was 6.9/100 000 inhabitants and the case-
fatality rate 2.6%. Thereafter, a decline in incidence was detected until 2014. During 2015 and
2016 an increase in the incidence transpired, but this rise was fortunately not accompanied by
one in the case fatality ratio. Indeed, in 2016 the case fatality ratio was the lowest (0.6%).
Moreover, during the 2016 outbreak, the incidence (3.9/100 000 inhabitants) and the case
severity detected in the most vulnerable population (infants 0–2 months) were both lower
than those in 2011. Consistent with this pattern, in 2016, in the most populated province
of Argentina (Buenos Aires), the case percentage with laboratory-positive results indicating
a high number of symptoms (59.1% of the total cases) diminished compared with that
detected in the 2011 outbreak without maternal immunisation (71.9%). Using the mathemat-
ical model of pertussis transmission we previously designed, we assessed the effect of vaccin-
ation during pregnancy on infant incidence. From comparisons between the epidemiological
data made through calculations, emerged the possibility that vaccinating women during preg-
nancy would benefit the infants beyond age 2 months, specifically in the 2–12-month cohort.
Introduction
Pertussis or whooping cough is an acute infectious respiratory disease that can affect indivi-
duals of any age [1–3]. However, infants with <1 year old and particularly those younger
than 6 months bear the largest disease burden. Severe morbidity and death are most common
in infants [4–6]. In the last two decades, the incidence of the disease has increased in many
countries; with around 16 million cases occurring per year associated with approximately
200 000 deaths [7]. Most of those cases have been reported in developing countries; although
in recent years large outbreaks have also been detected in developed countries, even in those
with high vaccination rates [7–9]. This epidemiological situation has caused concern, forcing
the healthcare systems to reinforce and/or implement strategies that, over the short term,
improve the control of the disease – at least in that most vulnerable population. In this
sense, different countries including Argentina added new boosters in the vaccination schedules
following the recommendations of international entities [10–18]. Vaccinating women during
pregnancy with an acellular vaccine (aP) is the most recent strategy recommended (2011) by
the Advisory Committee on Immunization Practices from USA (ACIP) in an effort to reduce
the burden of pertussis in newborns and infants [11]. When countries decided to implement
maternal immunisation (MI), information on the safety of this strategy in the mother and the
fetus or its real impact on the epidemiology of pertussis, were scarce. The safety of pertussis
vaccination during pregnancy was first studied in the UK [15], but more recently in Mexico
[16]. In these and other studies, the safety of aP in pregnant women was confirmed. That
aP induces high concentrations of antibodies during pregnancy that are transferred via the pla-
centa to the fetus is now also known [15, 17, 18]. The effectiveness of MI in preventing infant
pertussis was recently evaluated in England (2016), the USA (California, 2017) and Argentina
(2016) [19–21]. The finding from England was that in the 3 years following the introduction of
an MI programme, vaccine effectiveness against confirmed pertussis had been sustained over
90% [19]. In California, the estimated MI effectiveness in protecting against pertussis was
91.4% during the first 2 m in neonates [21]. In Argentina, a pronounced decrease in the
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mortality rates was detected 2 years after the introduction of
the aP booster during pregnancy [22]. All these data are highly
encouraging regarding the use of this vaccination strategy to diminish
the risk of pertussis in the most vulnerable population. These find-
ings, however, should be interpreted with care since the data were
obtained under different epidemiological situations. In England
and Argentina, the data were obtained after outbreaks, when a decline
in pertussis cases would be expected. The California data were
obtained during a period that included two outbreaks (https://
www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%
20Library/Immunization/2017Jan23PertussisReport.pdf) in which
parameters such as pertussis risk and/or maternal coverage, are not
the same during an outbreak as when the outbreak is over.
In order to more completely understand the impact of MI in
countries that introduced maternal vaccination immediately
after an outbreak, in this study, new data on infant-pertussis epi-
demiology from Argentina including comparisons between two
similar epidemiological situations were presented. These two epi-
demiological situations refer to two outbreaks that occurred
before and after the introduction of maternal vaccination. All
these epidemiological situations were simulated using the math-
ematical model of transmission of pertussis previously designed
by us [23]. From comparisons between the estimated infant inci-
dences during outbreaks occurring before and after the introduc-
tion of MI with epidemiological data, emerged new information
on the potential benefits of maternal vaccination.
Materials and methods
Population studied
In this work, we describe the pertussis pattern in Argentina as a
whole and in the most populated region of the country, the
Buenos Aires province. In Argentina, the vaccination schedule
includes three primary doses at 2, 4 and 6 m and two boosters
at 18 m and school-entry (5–6 years) with whole-cell vaccine.
aP boosters for adolescents, healthcare workers in contact with
infants under 12 m, household contacts of very low birthweight
infants and during pregnancies are also included.
In Argentina, MI was implemented in 2012 for a single preg-
nancy after the 20th week of pregnancy. From 2016, MI is man-
datory for all pregnancies.
In cases of incomplete schemes, if there are no contraindica-
tions, catch-up vaccination schedule is applied following the
recommendations of the National Ministry of Health.
The official data on immunisation coverage included in this
work are from the National Ministry of Health.
Pertussis epidemiological surveillance
The pertussis epidemiological data used here were extracted both
from the National Health Surveillance System of Argentina
(SNVS), which entity receives complaints of diseases involving a
compulsory notification, including pertussis and from the
Pertussis Reference Laboratory (PRL) in La Plata. The SNVS
information comprises gender, age, duration of symptoms with-
out the specification of the symptom, vaccination status (vaccin-
ation schedule complete or incomplete depending on the
patient’s age and the number of doses received) and the labora-
tory results. The PRL data include more detailed information
extracted from patients attended in hospitals or healthcare centers
in Buenos Aires.
Pertussis-case definitions
The clinical case definition used in Argentina is based on the clin-
ical criteria of the United States Centers for Disease Control and
Prevention (CDC) and the WHO (http://www.cdc.gov/ncphi/
disss/nndss/casedef/pertussis_current.htm, www.who.int/entity/
immunization_monitoring/diseases/pertussis_surveillance/en/index.
html), but that information was stratified according to age (http://
www.msal.gob.ar/images/stories/pdf/coqueluche-recomendaciones-
definiciones.pdf). Suspected pertussis in infants younger than age
6 months included those with acute respiratory illness and at least
one of the following signs: apnea, cyanosis, stridor, vomiting after
coughing or paroxysmal cough. In patients between 6 months and
11 years, suspected pertussis required a persistent cough for 14
days or more accompanied by one or more of the following symp-
toms: a paroxysmal cough, inspiratory whoop or vomiting after
coughing without other apparent cause. Suspected pertussis in
patients older than 11 years of age required a persistent cough
for 14 or more days without other accompanying symptoms.
A diagnosis of pertussis was confirmed in patients with sus-
pected illness by Bordetella pertussis isolation in culture, amplifi-
cation of B. pertussis-specific DNA by the polymerase-chain
reaction and/or serology by anti(pertussis-toxin IgG) and in
patients with pathognomonic symptoms who were epidemiologi-
cally linked to a laboratory-confirmed case.
Mathematical model
An age-structured compartmental deterministic model previously
developed by us was used in the present analysis [23, 24]. A
detailed description of the model, the differential equations that
describe the dynamics of the disease, and the parameters used
for the calculations are presented in the supplementary material.
In Figure 1, we briefly described how MI was considered. The sus-
ceptible individuals that get in contact with infectious individuals
can acquire a full symptomatic infection, while individuals with
an increasing level of immunity acquire a less severe infection
or eventually do not become infected if they receive at least
three effective vaccine doses. Incidences of severe (s) and mild
(m) pertussis in age group i are computed in the model through
the equations:
Incs,i = liSi, Incm,i = liP1Ali
where Si and P1Ali are the fractions of the population in age group i
that are susceptible and with the primary immune response against
pertussis, respectively, and λi is the force of infection (the rate at
which S or PAI individuals become infected). Computation of λi
involves an accounting of the contacts of infants in age-group i
with infected individuals of all age groups. Then, λi is a dynamic
variable of the model that depends on the nature of the transmis-
sion of the disease among the different age groups.
To evaluate the impact of MI on the pertussis dynamics, we
started in the stationary state of our model without including
MI and introduced a perturbation of the system by transferring
20% of the individuals from the Susceptible to the Recovered
classes to mimic the typical periodicity of pertussis outbreaks.
This approach is a common practice when using deterministic
models [24, 25] to obtain the oscillations that other considerations
(such as stochasticity, for example) would introduce. After the
disturbance, the system is left to evolve; and, at a chosen moment
in the dynamics, MI is introduced.
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Results
Pertussis epidemiology patterns in Argentina before and after
the introduction of maternal vaccination in 2012
In most parts of Argentina, the DTP3 coverage during recent
years ranged between 91% and 95%. We need to note that the
coverage estimation is not homogenous throughout the country,
as some of the cities have coverage below 80% [26]. The official
data available on the MI coverage is 50.9%, 67.1% and 70.9%
for the respective years 2012, 2013 and 2014; but for 2015 and
2016 the figures are somewhat lower at 61.7% and 65.6%.
According to the Comprehensive Bulletin of Surveillance of
the Ministry of Health, from 2008 to 2010 a decline in the inci-
dence of pertussis cases was observed (http://www.msal.gob.ar/
index.php/home/boletin-integrado-de-vigilancia), but a major
outbreak was detected in 2011 with an incidence of confirmed
pertussis cases of 6.9 per 100 000 inhabitants and a case fatality
ratio of 2.6%. From 2012 to 2014 a sustained decline in the inci-
dence from 4.7 to 1.4 per 100 000 was registered. This decline
was accompanied by a decrease in the case fatality ratio to
1.7% in 2012, 0.9% in 2013 and 1.1% in 2014. In 2015 and in
2016 increases in the incidence were detected at 2.2 in 2015
and 3.9 in 2016 (Fig. S1). Fortunately, these rises in the inci-
dences were not accompanied by case fatality ratios: at 1.0%
and 0.6% for 2015 and 2016, respectively. All these data would
indicate that the MI effects a reduction in the case fatality
ratio – that is, the strategy reduces the severity of those pertussis
cases that would otherwise be fatal. Another significant effect of
the MI was detected in the 2016 outbreak, one that had been
expected because of the cyclicity of the disease. That the max-
imum incidence for each outbreak was different – 6.9 for the
2011 outbreak detected before the introduction of the MI and
3.9 for the 2016 episode evidenced after the introduction of
MI – is noteworthy. The MI would, therefore, appear to reduce
the magnitude of the outbreaks as well, though not affecting the
occurrence.
In terms of the distribution of confirmed cases with respect to
patient age during this 2010–2016 period, of the total confirmed
cases each year, 25–29% corresponded to infants of less than 2 m
of age and 62–89% to infants of less than 6 m. The majority of the
notified pertussis cases between 2010 and 2016 corresponded to
the more populated provinces such as Buenos Aires, Córdoba,
Santa Fe and Mendoza [20].
The next section will focus on the description of the epidemio-
logical data of Buenos Aires since more detailed information is
available. This epidemiological information was extracted from
the data collected by the RPL and the online laboratory softward
named SIVILA (Sistema de Vigilancia laboratorial).
Pertussis epidemiology of Buenos Aires
During 2010–2016 in Buenos Aires, a total of 18 234 clinical sam-
ples from pertussis-suspected cases were notified at SIVILA, from
which group 3519 (19.3%) were laboratory-confirmed. Figure 2A
summarises the distribution of the number of pertussis cases per
year. As occurred throughout the whole country, in the Buenos
Aires province two outbreaks were detected, one in 2011 and a
second in 2016. This province also experienced a sustained
decline in the number of cases during 2012–2014 followed by
an increase in 2015 and 2016. From the 18 234 clinical samples
of pertussis-suspected cases obtained during the period of
2010–2016, 10 197 samples (55.9% of the total) were received
by the PRL. Of this latter total, 1897 (18.6%) gave a positive
laboratory result. The distribution of cases analysed at the PRL
per year (Fig. 2B) exhibited a pattern similar to that of the
cases notified at SIVILA (Fig. 2A).
Since the PRL received a representative number of clinical
samples from patients whose epidemiology followed the same
Fig. 1. Schematic representation of the immune
status of individuals during the first 4 months of
life. In the first 4 months of life, individuals that
have not become infected may be in the suscep-
tible class, S (fully susceptible to infection) or in
the P1Al class (partial-acquired-immunity class
with the first degree of immunity). Individuals
born from non-immunised mothers are in the sus-
ceptible class but may increase their immunity
through the administration of an effective dose
of the DTP1 vaccine. The vertical dashed lines in
the figure indicate that age groups are weekly dis-
cretised into 2–4-month cohorts. A fraction of the
individuals is transferred to the P1Al class at each
week according to the vaccine efficacy and vac-
cine coverage per week taken from epidemio-
logical data. Individuals born from immunised
mothers are in the P1Al class until they are 2
months old; then, they lose their immunity and
enter the S class, unless they recover the first
degree of immunity through the administration
of an effective DTP1 dose. Individuals in the S
and P1Al classes may both become infected when
coming into contact with the pathogen; but indi-
viduals in the S class are assumed to be suscep-
tible to contracting a full symptomatic (severe)
disease, while individuals in P1Al class would
acquire a mild symptomatic (less severe) disease.
We assume that both infections (I1 and I2, respect-
ively) could be detected by the healthcare system,
but that only the severe disease may cause death.
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pattern as the one detected at the national level, the following ana-
lyses were carried out from the information collected by the PRL.
In particular, we compared the epidemiological data registered
during the two outbreaks detected, the first occurring before
(2011) and the second after (2016), when MI was introduced in
the healthcare calendar. First, we analysed the distribution of per-
tussis cases according to patient age during those two outbreaks
(Fig. 3). In each year of the period analysed, most of the cases
were detected in the groups of infants 0–2 and 2–4 m of age.
We were interested in noting that although during both outbreaks
the proportions of suspected cases in the 0–2 m-old group were
similar, the proportion of cases with positive laboratory results
diminished in 2016 (31.0%) relative to those detected in 2011
(34.5%). This decrease was also notable in the 2–4 m group
(34.5% in 2011 vs. 27.0% in 2016). Since we expected that the
greatest impact of the introduction of MI would be in the infants
with fewer than 2 m of age, we analysed whether the number of
cases with a high number of symptoms as well as the most severe
symptoms of the disease – i.e. paroxysm, apnea, cyanosis and
vomiting – diminished in this group during the outbreak occur-
ring after the introduction of MI. As shown in Figure 3C and
D, the proportion of pertussis cases with a high number of symp-
toms decreased during the 2016 outbreak. In 2016, the proportion
of cases with laboratory-positive results involving a high number
of symptoms (59.1% of the total cases) diminished in comparison
with data from the 2011 outbreak in the absence of MI (71.9%),
representing a decrease of about 18%.
Figure 3E and F illustrate how all the analysed symptoms dimin-
ished during the outbreak detected after the introduction of MI.
The greatest decrease was observed in the proportion of paroxysms
and vomits. All the data analysed here during the two similar epi-
demic situations (outbreaks) demonstrated the beneficial effect of
MI – not only with respect to the number of cases but also in
terms of the severity of the disease in the most vulnerable group
– but of even greater significance was the result that immunisation
during pregnancy reduced the case fatality ratio.
Estimations of the effect of MI by means of a mathematical
model of pertussis transmission
Here, we analysed the effect of MI through the use of our previ-
ously designed pertussis-transmission model [23, 27]. The pat-
terns in the incidences of severe pertussis in the 0–2 m-old
cohort is plotted in the top left graph of Figure 4A. These inci-
dences were calculated assuming that MI began immediately
after the outbreak, as transpired in Argentina in 2012 and with
the high DTP3-coverage scenario. For the 2016 peak, the model
predicted that the number of severe cases would be 36% of that
occurring without the introduction of MI.
Although the impact of MI on the incidence peak in the 0–
12 m age group in 2016 was lower than that observed for the
0–2 m cohort (Fig. 4B), the overall profile of the incidences in
both groups were similar. In 2016, the incidence in the 0–12 m
cohort was predicted to reach 71.5% of the calculated value in
the absence of MI. In addition, the effect of MI on the 0–12 m
group under a low DTP3-coverage scenario would be lower
(Fig. 4C): in 2016 the incidence was predicted to reach 80% of
the calculated value in the absence of MI instead of the 71.5%
Fig. 2. (A) Distribution of a number of pertussis cases notified at
the SIVILA network per year during 2010–2016 in the Buenos
Aires province. (B) Distribution of a number of pertussis cases
notified by the Reference Lab per year during 2010–2016 in
the Buenos Aires province. In both panels, the total number of
cases per year is plotted on the ordinate for each year indicated
on the abscissa. The numbers above the bars denote the precise
ordinate values. Grey bars, clinically suspected cases; black bars,
laboratory-confirmed cases.
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calculated for the higher DTP3-coverage scenario (Fig. 4B). The
most striking feature that emerges comparing Figure 4B and C
is the higher absolute values in the incidences in Figure 4C result-
ing from the low coverage considered for the primary series.
We also analysed the effect of introducing the MI at a different
stage in the dynamic cycle of the disease: both before and during an
outbreak. That the beginning of MI would directly affect the inci-
dence immediately after vaccine introduction was both striking and
significant. If MI had been introduced in 2010, for example, the
2011 peak for the incidence of 0–2 m olds would hardly have
occurred (Fig. 4A, upper right graph). In contrast, the decrease
in the calculated incidences at the 2016 peak appeared to be inde-
pendent of the time when MI began in relation to the initial out-
break (upper right and both lower graphs of Fig. 4A–C).
Comparisons between the reported data and the predictions
obtained with the model
We next sought to perform comparisons between the results
obtained with the model and the epidemiological data. To that
Fig. 3. Panel A: Proportions of suspected pertussis cases according to age during 2011 and 2016 outbreaks. Panel B: Proportions of pertussis cases with positive
laboratory results according to age during 2011 and 2016 outbreaks. Panel C: Proportion of suspected pertussis cases in the 0–2-month-old group according to the
number of symptoms in 2011 and 2016 outbreaks. Panel D: Proportion of cases in 0- to 2-month-old group with positive laboratory results according to the number
of symptoms in 2011 and 2016 outbreaks. Panel E: Proportion of suspected pertussis cases in 0- to 2-month-old group according to the type of symptoms during
the 2011 and 2016 outbreaks. Panel F. Proportion of cases in 0- to 2-month-old group with positive laboratory results according to the type of symptoms during the
2011 and 2016 outbreaks. In the six panels, the percentage of suspected (panels A, C and E) or laboratory-confirmed (B, D and F) cases of pertussis is plotted on
the ordinates for the four infant-age cohorts between ages 0 and 12 months (m; A and B), the number of symptoms recorded within each peer group (C and D), or
the type of symptoms experienced in each (E and F) on the abscissas. Black bars, 2011 outbreak; grey bars, 2016 outbreak.
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end, we had to compensate the known difference between the
epidemiological data and the calculations because of the underre-
porting of the epidemiological data. We defined a reporting factor
for different population groups as follows:
f Rg =
IncRg
IncAg
Where IncRg is the incidence computed from cases reported in
group ‘g’ and IncAg is the actual incidence in the same group.
We differentiated the 0–2 m old from 2–12 m old group and
severe disease from mild disease and evaluated the relative reported
incidence for the 0–1y age group in 2016 with respect to 2011:
A = Inc
R
0−12m(2016)
IncR0−12m(2011)
= Inc
C
s,0−2(2016) + fsympIncCm,0−2(2016) + fageIncCs,2−12(2016) + f ′sympfageIncCm,2−12(2016)
IncRs,0−2(2011) + fsympIncCm,0−2(2011) + fageIncCs,2−12(2011) + f ′sympfageIncCm,2−12(2011)
(1)
where IncAg was replaced by the incidences obtained from the
model calculations, IncCg . under the assumption that the model pre-
dicted the values of the actual incidences. We also introduced the
relative reporting factors
fage =
f Rs,2−12
f Rs,0−2
,
fsymp =
f Rm,0−2
f Rs,0−2
and
f ′symp =
f Rm,2−12
f Rs,2−12
.
These factors are the variables of our study and would account
for the relative reporting of severe cases between 2 and 12 m with
respect to those between 0 and 2 m ( fage), the relative reporting of
moderate cases with respect to the severe cases in the 0–2 m group
( fsymp) and the relative reporting of moderate cases with respect to
the severe cases in the 2–12 m group ( f ′symp). Assuming that these
factors are numbers between 0 and 1, the right side of Equation (1),
can be considered a function A( fage, fsymp, f ′symp) with the objective
of determining the set of possible numbers assigned to fage, fsymp,
f ′symp that give a value of A that is compatible with the epidemio-
logical observations presented in this work. These observations
indicate that the incidence in the 0–12-month group in
Argentina decreased to 56% in 2016 compared with 2011, similar
to that observed for Buenos Aires (61%). For those calculations
we considered A to be in the range: 0.55 <A < 0.65.
In Figure 5, we have shaded with light grey the set of values of
( fage, fsymp) which give values of A between 0.55 and 0.65 for dif-
ferent values of f ′symp where the calculated incidences IncCg used
in Equation (1) correspond to a high-coverage scenario and intro-
duction of aP in 2012 (upper left graphs of Fig. 4A and B). In our
analysis we also incorporated the quotient, B(t), between the cases
reported in the 0–2 m group and in 0–12 m group for a given ‘t’
year:
B(t)= Inc
R
0−2m(t)
IncR0−12m(t)
= Inc
C
s,0−2(t)+fsympIncCm,0−2(t)
IncCs,0−2(t)+fsympIncCm,0−2(t)+fageIncCs,2−12(t)+f ′symp fageIncCm,2−12(t)
(2)
This magnitude remains approximately constant ranging between
0.3 and 0.4 between 2011 and 2016 when computed from the epi-
demiological reports obtained in PRL. Between 2011 (0.35) and
2016 (0.30), a reduction of 15% occurred. In Figure 5 we have
shaded with dark grey the values of ( fage, fsymp) for different
fixed values of f ′symp that are compatible with a reduction of
between 10 and 20% of B(t) in Equation (2) when using the inci-
dences obtained by the model for the years 2011 and 2016. We
also considered only the values of fage, fsymp, f ’symp for which B
(t) was maintained between 0.3 and 0.4.
The figure indicates that in order to satisfy inequalities on B a
considerable report of the cases with moderate symptomatology
( fsymp > 0.4) and older than 2 m ( fage > 0.4) becomes necessary
while the contrary holds for inequalities on A. This analysis
demonstrates that no fage, fsymp, f′symp is compatible with the
two sets of epidemiological observations mentioned above.
Therefore the results predicted by our model are not compatible
with these epidemiological reports. In the supplementary mater-
ial, we carried out a sensitivity analysis that shows that these
results are robust for different possible values of some of the para-
meters included in the model. This conclusion led us to revise the
assumptions made in our model, particularly the one regarding
the duration of maternal immunity in infants. This assumption
was based on reports on the duration of maternal antibodies in
infants born to immunised mothers [16, 18]. However, it was
recently reported that MI has additional protection effect for
infants with more than 2 m who have received the first doses of
pertussis vaccine [21]. Though the impact on infants incidence
of this effect will be subject of a future work when more solid epi-
demiological information will be collected, here we analysed
whether this additional effect of MI could approximate the data
predicted by the model to the epidemiological data. To include
this aspect we performed some modifications to the model that
were described in the supplementary material (SM). Basically,
we considered that effectiveness of DTP1 in infants born to
vaccinated mother was 80% higher than that of infants born to
non-vaccinated mothers. We could observe that by increasing
the effectiveness of the DTP1, the incidence of severe cases in
0–12 m group is reduced by 50% in the 2016 peak with respect
to the 2011 peak, whereas when this increase in the DTP1 was
not considered, this reduction was only 28.5%. With these data,
we obtained the Figure 6 in which interestingly a region of values
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of the relative reporting factors ( f′symp≈ fsymp≈ 0.25, fage≈ 0.8)
that makes possible the compatibility between calculation and
epidemiological data could be observed.
Discussion
To shed light on the effects of MI, in the work reported here, we
have provided not only data from the Argentine pertussis-
surveillance system but also information arising from comparisons
between two similar epidemiological situations (outbreaks) in
which the sole evident variable was the use of the vaccination of
pregnant women. In particular, we compared the data collected dur-
ing two outbreaks: one in which the pregnant women were not
aP-vaccinated (2011) and the other occurring in 2016 after the intro-
duction of MI (2012). In 2012, the maternal pertussis-vaccination
coverage was relatively high (50.9%) since that year was the one in
which the policy was introduced in the country. The improvement
in maternal-vaccination coverage in the following years was accom-
panied by a decrease in the case fatality ratio (0.6% in 2016).
After 2011, the incidence rate likewise exhibited a clear
decrease in the confirmed cases throughout the whole country
that continued until 2014. After that period, as expected from
the cyclicity of the disease, an increase in the number of cases
was observed and in 2016 another outbreak was detected. The
2016 incidence peak, however, was lower than that detected in
the 2011 outbreak. In Buenos Aires, the epidemiologic pattern
was similar to that detected in the whole country. For this prov-
ince in 2016, a reduction in the number of cases in 0–2 m-old
infants presenting paroxysms and/or vomiting was detected.
Calculations performed with our pertussis-transmission model
enabled us to analyse whether the MI had a genuine impact on
the reduction of pertussis cases beyond the fall in cases that
would be expected to occur after an outbreak. Our model predicts
for a high DTP3 coverage scenario a 64% reduction of the inci-
dence of severe cases in the 0–2 m-old group in 2016 peak with
respect to 2011 peak, and 28.5% reduction of the incidence in
severe cases of 0–12 m-old group. We observed that the predicted
reduction in the number of cases occurred independently of the
time when MI was started. What was noteworthy, however, was
that the greatest effect was realised in the hypothetical case in
which MI is performed before the outbreak.
When we attempt a comparison of the epidemiological data
with those calculated with the model, we found that no values
for the considered underreporting factors rendered the calcula-
tions compatible with the data. This discrepancy could result
because the calculations were performed assuming that MI had
an effect on infants only up to 2 m of age. This assumption
based on the duration of maternal antibodies in infants would
appear to be incorrect in that MI probably has an effect lasting
beyond the first 2 m of life. In agreement with this hypothesis,
Baxter et al. reported a retrospective cohort study of infants
born in California from 2010 to 2015 [21] where they observed
that MI was highly protective against pertussis, especially in the
first 2 m of life, but also up to the first year. The authors also
found that MI provides additional protection for infants who
received the first dose of vaccine (DTP1). Interesting, when we
considered this effect of MI in the model by increasing the effect-
iveness of the DTP1, the incidence of severe cases in 0–12 m is
reduced by 50% in the 2016 peak with respect to the 2011 peak
which would allow a better approximation between the calcula-
tion and the data reported.
Fig. 4. (A): Dynamic evolution of severe-pertussis incidence in the 0–2-month (m) age
group predicted by the model after the introduction of the aP booster to pregnant
women. Each panel plots the incidence pattern in cases per year per 100 000 on
the ordinate for introduction of the booster at a different stages in the dynamic
cycle (solid line) of the disease within the years from 2010 to 2020 indicated on
the abscissa compared with the expected pattern in the absence of the booster
(dashed line). The upper-left graph corresponds to the actual introduction of the
booster (in 2012, after the 2011 incidence peak). The upper-right, lower-left and
lower-right panels depict the hypothetical situations in which the booster was intro-
duced before the first peak, exactly at the peak, or at the first minimum after the
peak, respectively. The calculations were performed on the basis of a high
DTP3-coverage scenario (95%). (B) The same as A but for the incidence in the
0–12-month age group. (C) The same as (B), but for a low DTP3-coverage scenario
(80%).
864 G. Fabricius et al.
. https://doi.org/10.1017/S0950268818000808
Downloaded from https://www.cambridge.org/core. IP address: 54.70.40.11, on 02 Sep 2019 at 12:30:35, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms
Our results support the relevance of MI in the reduction of
cases in the most vulnerable population, in particular, in infants
between 0–2 m old, who are not yet old enough to receive the
first dose of pertussis vaccine. Our hope is that this evidence
could also be used in the community and public campaigns
aimed at improving the overall vaccination rates both during
pregnancy and in the primary series.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0950268818000808
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